Medical Device Industry Criticizes India's Draft Regulation Bill
India's medical device industry opposes a 2026 bill treating devices like drugs, citing potential harm to innovation and investment.
The medical device industry in India is voicing strong opposition to the proposed Drugs, Medical Devices and Cosmetics Bill, 2026. The bill, which is currently under inter-ministerial review, seeks to regulate medical devices in a manner similar to pharmaceuticals, a move that industry stakeholders argue could stifle innovation and deter investment.
Industry Pushback Against Drug-Like Regulation
Industry representatives, including associations of manufacturers and healthcare providers, have formally expressed their concerns to the Union Health Minister. They argue that the draft legislation fails to recognize the distinct nature of medical devices, which are engineering products rather than pharmaceuticals. The bill's approach, they claim, does not align with international practices where devices are regulated through risk-based assessments and quality management systems, rather than stringent drug-style penalties.
The draft bill introduces severe penalties, including imprisonment for lapses such as labeling errors or documentation mistakes, even in the absence of harm. This contrasts sharply with regulatory frameworks in regions like the European Union, the United States, and Japan, where administrative enforcement is preferred.
Impact on Manufacturing and Innovation
Stakeholders warn that the bill could impede India's goal of becoming a global hub for medical device manufacturing. The industry's letter to the government, dated August 8, highlights the potential negative impact on manufacturing and innovation. The letter criticizes the use of drug-centric terminology like "adulterated" and "spurious," which they argue is inappropriate for engineering products.
By maintaining a pharmaceutical-centric regulatory language, the bill risks creating a challenging environment for the medical device sector, which relies on engineering precision rather than pharmaceutical standards. The industry is calling for a regulatory framework that supports growth and innovation, rather than imposing restrictive measures.
Calls for a Revised Approach
Medical device companies and healthcare groups are urging the government to reconsider the bill's provisions. They emphasize the need for a regulatory system that reflects the unique characteristics of medical devices, promoting safety without stifling innovation. As the draft bill undergoes further consultation, industry leaders hope for amendments that will better support the sector's development.
The outcome of this regulatory debate will have significant implications for the future of India's medical device industry, which is poised for growth in a global market. Stakeholders are keenly watching for any revisions to the draft that might align it more closely with international standards and practices.